GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Short Percentage of Float

XSpray Pharma AB (STU:6XP) Short Percentage of Float


View and export this data going back to 2018. Start your Free Trial

What is XSpray Pharma AB Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of XSpray Pharma AB's Short Percentage of Float

For the Biotechnology subindustry, XSpray Pharma AB's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XSpray Pharma AB's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's Short Percentage of Float falls into.


;
;

XSpray Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (STU:6XP) » Definitions » Short Percentage of Float
Comparable Companies
OSTO:EGTX OSTO:GENO OSTO:SANION OSTO:SYNACT OSTO:VICO OSTO:DMYD B XSAT:HAMLET B OSTO:HNSA OSTO:IBT B OSTO:BINV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
XSPRAY:Sweden 0GHZ:UK
Address
Scheeles vag 2, Solna, SWE, SE-171 65
Website
https://www.xspraypharma.com
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.

XSpray Pharma AB Headlines

No Headlines